- Home
- BRLT vs LSTA Comparison
BRLT vs LSTA Comparison
Compare BRLT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- LSTA
- Stock Information
- Founded
- BRLT 2005
- LSTA 1980
- Country
- BRLT United States
- LSTA United States
- Employees
- BRLT N/A
- LSTA N/A
- Industry
- BRLT Consumer Specialties
- LSTA Misc Health and Biotechnology Services
- Sector
- BRLT Consumer Discretionary
- LSTA Health Care
- Exchange
- BRLT Nasdaq
- LSTA Nasdaq
- Market Cap
- BRLT 22.6M
- LSTA 20.0M
- IPO Year
- BRLT 2021
- LSTA N/A
- Fundamental
- Price
- BRLT $1.50
- LSTA $2.39
- Analyst Decision
- BRLT Hold
- LSTA Strong Buy
- Analyst Count
- BRLT 4
- LSTA 1
- Target Price
- BRLT $2.20
- LSTA $15.00
- AVG Volume (30 Days)
- BRLT 40.5K
- LSTA 13.3K
- Earning Date
- BRLT 05-06-2025
- LSTA 05-08-2025
- Dividend Yield
- BRLT N/A
- LSTA N/A
- EPS Growth
- BRLT N/A
- LSTA N/A
- EPS
- BRLT 0.03
- LSTA N/A
- Revenue
- BRLT $422,161,000.00
- LSTA $1,000,000.00
- Revenue This Year
- BRLT $3.81
- LSTA N/A
- Revenue Next Year
- BRLT $4.48
- LSTA N/A
- P/E Ratio
- BRLT $47.98
- LSTA N/A
- Revenue Growth
- BRLT N/A
- LSTA N/A
- 52 Week Low
- BRLT $1.25
- LSTA $1.87
- 52 Week High
- BRLT $2.75
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- BRLT 50.92
- LSTA 60.67
- Support Level
- BRLT $1.37
- LSTA $1.91
- Resistance Level
- BRLT $1.60
- LSTA $2.09
- Average True Range (ATR)
- BRLT 0.12
- LSTA 0.18
- MACD
- BRLT 0.00
- LSTA 0.06
- Stochastic Oscillator
- BRLT 65.03
- LSTA 100.00
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.